Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL108864 | 0.87 | CA2 (0.61) | CA2TDP1ALDH1A1CA1CYP2C19 | |
| SCHEMBL107903 | 0.78 | CES2 (0.63) | CA2TDP1ALDH1A1CA1FFAR3 | |
| SCHEMBL108375 | 0.77 | — | — | |
| SCHEMBL13879016 | 0.76 | TSHR (0.40) | CA2TDP1ALDH1A1FFAR3 | |
| SCHEMBL17425080 | 0.76 | CA2 (0.44) | CA2TDP1ALDH1A1CA1FFAR3 | |
| SCHEMBL31346305 | 0.75 | CA2 (0.55) | CA2TDP1ALDH1A1CA1CYP2C19 | |
| SCHEMBL10568531 | 0.74 | TDP1 (0.33) | CA2TDP1ALDH1A1FFAR3 | |
| SCHEMBL20832141 | 0.74 | CA2 (0.48) | CA2TDP1ALDH1A1CA1CYP2C19 | |
| SCHEMBL27986649 | 0.74 | CA2 (0.48) | CA2TDP1ALDH1A1CA1CYP2C19 | |
| SCHEMBL9319991 | 0.74 | CA2 (0.32) | CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2463374-A2 | Isolated alcohol dehydrogenase enzymes and uses thereof | Bio Architecture Lab, Inc. (US) | 2012-06-13 | — | — | EP | claimed |
| EP-2195440-A2 | BIOFUEL PRODUCTION | Bio Architecture Lab, Inc. (US) | 2010-06-16 | — | — | EP | claimed |
| US-20090155873-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-18 | — | — | US | claimed |
| US-20090139134-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-04 | — | — | US | claimed |
| WO-2009046375-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| WO-2009046370-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| EP-3230463-B2 | RAPID PRETREATMENT | APALTA PATENTS OUE (EE) | 2025-07-16 | — | — | EP | disclosed |
| US-20240425893-A1 | RAPID PRETREATMENT | Apalta Patents OÜ (EE) | 2024-12-26 | — | — | US | disclosed |
| US-12054761-B2 | Rapid pretreatment | Apalta Patents OÜ (EE) | 2024-08-06 | — | — | US | disclosed |
| US-11821047-B2 | High pressure zone formation for pretreatment | Apalta Patent OÜ (EE) | 2023-11-21 | — | — | US | disclosed |
| US-20230295678-A1 | RAPID PRETREATMENT | Apalta Patents OÜ (EE) | 2023-09-21 | — | — | US | disclosed |
| EP-4098750-A1 | RAPID PRETREATMENT | Sweetwater Energy, Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-3230463-B1 | RAPID PRETREATMENT | SWEETWATER ENERGY INC (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-1231207-A1 | NOVEL BIPYRIDYL DERIVATIVES | Sankio Chemical Co., Ltd. (JP) | 2002-08-14 | — | — | EP | disclosed |
| EP-0780340-B1 | Intercalates and exfoliates formed with functional monomeric organic compounds; composite materials containing same and methods of modifying rheology therewith | AMCOL INTERNATIONAL CORP (US) | 2002-03-20 | — | — | EP | disclosed |
| US-5804613-A | Intercalates and exfoliates formed with monomeric carbonyl-functional organic compounds, including carboxylic and polycarboxylic acids; aldehydes; and ketones; composite materials containing same and methods of modifying rheology therewith | AMCOL INTERNATIONAL CORPORATION (US) | 1998-09-08 | — | — | US | disclosed |
| EP-0780340-A1 | Intercalates and exfoliates formed with functional monomeric organic compounds; composite materials containing same and methods of modifying rheology therewith | AMCOL INTERNATIONAL CORPORATION (US) | 1997-06-25 | — | — | EP | disclosed |
| EP-0654460-B1 | Process for the C-alkylation of a ketonic compound | RHONE POULENC CHIMIE (FR) | 1997-06-18 | — | — | EP | disclosed |
| US-5618982-A | SIMPLE INDUSTRIAL PROCESS OF CATALYZING IN PRESENCE OF METALLIC PHOSPHATES | RHONE-POULENC CHIMIE (FR) | 1997-04-08 | — | — | US | disclosed |
| EP-0654460-A1 | Process for the C-alkylation of a ketonic compound | RHONE-POULENC CHIMIE (FR) | 1995-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090139134-A1 | BIOFUEL PRODUCTION | MGAM, DCXR, MANBA | CA2 3146/4885TDP1 2746/4885ALDH1A1 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.